

## ODN 1018

<b>Cat. No.:</b>	HY-150724	
<b>CAS No.:</b>	937402-51-2	
<b>Molecular Weight:</b>	7150	
<b>Sequence:</b>	DNA, d(P-thio)(T-G-A-C-T-G-T-G-A-A-C-G-T-T-C-G-A-G-A-T-G-A)	DNA, d(P-thio)(T-G-A-C-T-G-T-G-A-A-C-G-T-T-C-G-A-G-A-T-G-A)
<b>Target:</b>	Toll-like Receptor (TLR)	
<b>Pathway:</b>	Immunology/Inflammation	
<b>Storage:</b>	-20°C, sealed storage, away from moisture	
	* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)	

### SOLVENT & SOLUBILITY

#### In Vitro

H<sub>2</sub>O : ≥ 100 mg/mL (13.99 mM)  
 \* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg
		Concentration	1 mg	5 mg	10 mg
	1 mM		0.1399 mL	0.6993 mL	1.3986 mL
	5 mM		0.0280 mL	0.1399 mL	0.2797 mL
	10 mM		0.0140 mL	0.0699 mL	0.1399 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

ODN 1018 (1018 ISS), an oligodeoxynucleotide, is a TLR-9 agonist. ODN 1018 is also a synthetic immunostimulatory sequence that can be used as vaccine adjuvant. Sequence: 5'-TGACTGTGAACGTTTCGAGATGA-3'<sup>[1][2]</sup>.

#### IC<sub>50</sub> & Target

TLR9

### REFERENCES

[1]. Friedberg JW, et al. Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma. Br J Haematol. 2009 Aug;146(3):282-91.

[2]. Eng NF, et al. The potential of 1018 ISS adjuvant in hepatitis B vaccines: HEPLISAV™ review. Hum Vaccin Immunother. 2013 Aug;9(8):1661-72.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA